LY3849891 + Placebo
Phase 1Active 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Conditions
Metabolic Dysfunction-Associated Steatohepatitis (MASH), Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD)
Trial Timeline
Jun 8, 2022 → May 1, 2026
NCT ID
NCT05395481About LY3849891 + Placebo
LY3849891 + Placebo is a phase 1 stage product being developed by Eli Lilly for Metabolic Dysfunction-Associated Steatohepatitis (MASH). The current trial status is active. This product is registered under clinical trial identifier NCT05395481. Target conditions include Metabolic Dysfunction-Associated Steatohepatitis (MASH), Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD).
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05395481 | Phase 1 | Active |
Competing Products
20 competing products in Metabolic Dysfunction-Associated Steatohepatitis (MASH)